US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer

• Stacy S. Shord,
• Hao Zhu,
• Jiang Liu,
• Atiqur Rahman,
• Brian Booth,
• Issam Zineh

Affiliations

Stacy S. Shord

Division of Cancer Pharmacology II (DCPII), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA

Hao Zhu

Division of Pharmacometrics (DPM), OCP, OTS, CDER FDA Silver Spring Maryland USA

Jiang Liu

Division of Pharmacometrics (DPM), OCP, OTS, CDER FDA Silver Spring Maryland USA

Atiqur Rahman

Division of Cancer Pharmacology II (DCPII), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER) US Food and Drug Administration (FDA) Silver Spring Maryland USA

Brian Booth

Division of Cancer Pharmacology I (DCPI), OCP, OTS, CDER FDA Silver Spring Maryland USA

Issam Zineh

OCP, OTS, CDER FDA Silver Spring Maryland USA